Advanced search
Publication Cover
Postgraduate Medicine Volume 124, 2012 - Issue 4
Submit an article Journal homepage
43
Views
8
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes and Concomitant Disorders

Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus: Clinical Results in Subgroups of Patients Using Different Concomitant Medications

Richard Pencek Amylin Pharmaceuticals, Inc., San Diego, CACorrespondence[email protected]
, PhD,
Steven C. Brunell Amylin Pharmaceuticals, Inc., San Diego, CA
, PhD,
Yan Li Amylin Pharmaceuticals, Inc., San Diego, CA
, PhD,
Byron J. Hoogwerf Eli Lilly and Company, Indianapolis, IN
, MD &
James Malone Eli Lilly and Company, Indianapolis, IN
, MD
Pages 33-40 | Published online: 13 Mar 2015

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Michael Grimm, Jenny Han, Carole Weaver, Pete Griffin, Christine T. Schulteis, Haiying Dong & Jaret Malloy. (2013) Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials. Postgraduate Medicine 125:3, pages 47-57.
Read now

Articles from other publishers (6)

Shurui Hong. (2023) Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes. BIO Web of Conferences 61, pages 01006.
Crossref
Kumiko Hamano, Hiroshi Nishiyama, Akiko Matsui, Manaka Sato & Masakazu Takeuchi. (2017) Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. Endocrine Journal 64:4, pages 449-456.
Crossref
Yukiko Onishi, Tomonori Oura, Hiroshi Nishiyama, Sumika Ohyama, Masakazu Takeuchi & Noriyuki Iwamoto. (2016) Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocrine Journal 63:3, pages 263-273.
Crossref
C. Wysham, M. Grimm & S. Chen. (2013) Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes, Obesity and Metabolism 15:10, pages 871-881.
Crossref
R. M. Bergenstal, Y. Li, T. K. Booker Porter, C. Weaver & J. Han. (2012) Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks . Diabetes, Obesity and Metabolism 15:3, pages 264-271.
Crossref
Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber & Carol H. Wysham. (2012) Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice 18, pages 6-26.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.